Synergistic Disruption of OXPHOS in Cancer: Insights from LRPPRC Inhibition and Dasatinib Combination

Study Background and Research Question

Mitochondrial oxidative phosphorylation (OXPHOS) is a cornerstone metabolic pathway for many cancers, particularly those with high metastatic potential or stem-like features. Tumor cells often depend on OXPHOS for their energetic and biosynthetic needs, distinguishing them from normal tissues that may rely more on glycolysis or have slower mitochondrial turnover. While several OXPHOS inhibitors have demonstrated anti-tumor effects, these agents typically target single OXPHOS complexes, resulting in incomplete pathway inhibition and unwanted toxicity due to OXPHOS dependency in non-malignant cells. The research led by Chen et al. (Pharmaceuticals 2026, 19, 472) addresses a fundamental question: Can rational drug combinations more effectively and selectively disrupt OXPHOS in cancer, thereby overcoming the limitations of current monotherapies?

Key Innovation from the Reference Study

The pivotal innovation in this work is the identification and mechanistic dissection of a combination therapy—LRPPRC inhibition plus dasatinib—that achieves a dual-genome blockade of OXPHOS. LRPPRC, an RNA-binding protein, is critical for stabilizing mitochondrial gene transcripts required for OXPHOS complex assembly. Its overexpression in many epithelial tumors marks it as a selective vulnerability. By combining a small-molecule LRPPRC degrader (OCBI) with dasatinib, a clinically approved multi-kinase inhibitor, the authors create a strategy that simultaneously suppresses mitochondrial-encoded and nuclear-encoded OXPHOS gene products. This dual-targeting approach is novel and addresses the shortcomings of prior OXPHOS inhibitors by providing both greater efficacy and tumor selectivity (reference).

Methods and Experimental Design Insights

The study utilized a high-throughput screening platform to systematically evaluate 1,376 FDA-approved compounds in isogenic cancer cell models with either intact or depleted LRPPRC. Primary models included A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cells, both previously shown to be OXPHOS-dependent. Hits were prioritized based on their ability to synergize with LRPPRC degrader-based OCBI therapy. Hits were validated across multiple cancer cell lines using both genetic ablation and pharmacological inhibition of LRPPRC. Mechanistic studies involved transcriptome profiling to distinguish nuclear- and mitochondrial-encoded OXPHOS gene expression following treatment with dasatinib, LRPPRC inhibition, or the combination.

Protocol Parameters

• High-throughput compound screening: Assessed 1,376 FDA-approved molecules for synergy with LRPPRC inhibition in cancer cell models.
• LRPPRC inhibition: Achieved via genetic knockout or small-molecule degraders (e.g., Gossypol Acetate, T96); duration and dosing for maximal effect tailored per cell line.
• Dasatinib treatment: Applied at clinically relevant concentrations (typically 10–100 nM) to interrogate nuclear OXPHOS gene suppression.
• Transcriptome analysis: RNA-seq or qPCR used to profile differential gene expression from nuclear and mitochondrial genomes post-treatment.
• Synergy validation: Cell viability, apoptosis, and mitochondrial function assays confirmed combination efficacy.

Core Findings and Why They Matter

Dasatinib emerged as the most robust synergistic partner for LRPPRC inhibition. Mechanistically, dasatinib selectively downregulated nuclear-encoded OXPHOS genes, whereas LRPPRC inhibition predominantly affected mitochondrial DNA-encoded OXPHOS transcripts. The combination led to a coordinated and near-complete blockade of OXPHOS function in cancer cells, resulting in pronounced cytotoxicity. Notably, this dual-genome approach exploits the unique metabolic dependencies of tumor cells with high LRPPRC expression and rapid mitochondrial turnover, while sparing normal tissues characterized by lower LRPPRC and slower mitochondrial renewal. These results provide a strong mechanistic rationale for clinical development of this combinatorial strategy, particularly in tumors exhibiting OXPHOS addiction (reference).

Comparison with Existing Internal Articles

Several internal resources underscore the technical importance of preserving protein integrity during OXPHOS-targeted research:

• The article "Protease Inhibitor Cocktail: EDTA-Free Strategies for Protein Stability" describes how EDTA-free, broad-spectrum protease inhibitors facilitate reproducible protein extraction in OXPHOS-focused workflows, directly relevant to studies using kinase inhibitors and mitochondrial modulators.
• "Protease Inhibitor Cocktail: Enhancing Protein Stability in OXPHOS Research" highlights the compatibility of EDTA-free cocktails with phosphorylation and metalloprotein assays, which is critical when profiling kinase signaling (e.g., with dasatinib) alongside OXPHOS disruption.
• "Enhancing OXPHOS Research: Precision Protease Inhibition for Translational Impact" directly bridges the need for robust sample integrity to the emerging strategies in dual-genome OXPHOS targeting, as demonstrated by the reference study.

Collectively, these articles support the workflow choices made in Chen et al., emphasizing that rigorous cell lysate protease inhibition is foundational for reliable protein and phosphoprotein analysis in OXPHOS-targeted cancer research.

Limitations and Transferability

While the mechanistic synergy between LRPPRC inhibition and dasatinib is compelling, several limitations should be noted. First, the study's primary findings are based on in vitro cancer cell models; in vivo efficacy and toxicity, especially in the context of normal tissue OXPHOS requirements, remain to be fully validated. Second, the dependency on high LRPPRC expression for selectivity may limit applicability to specific tumor subtypes. Third, while dasatinib is FDA-approved, its kinase inhibition profile is broad, raising considerations about off-target effects. Despite these caveats, the dual-genome blockade concept represents a significant advance and provides a rational framework for future translational studies.

Research Support Resources

For researchers seeking to replicate or extend dual OXPHOS inhibition workflows, robust sample integrity is paramount. The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K4002) from APExBIO is designed to maintain protein stability during cell and tissue extraction, supporting sensitive assays such as Western blotting, kinase activity measurements, and immunoprecipitations. Its EDTA-free formulation ensures compatibility with metalloprotease and phosphorylation studies, aligning with the requirements of OXPHOS and kinase-focused cancer research. Proper use of such protein stability enhancers can help ensure reproducible, high-quality data in complex multi-drug and metabolic targeting studies.